Number of the records: 1
Synthesis and in vitro Study of Artemisinin/Synthetic Peroxide-Based Hybrid Compounds against SARS-CoV-2 and Cancer
- 1.
SYSNO ASEP 0556680 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Synthesis and in vitro Study of Artemisinin/Synthetic Peroxide-Based Hybrid Compounds against SARS-CoV-2 and Cancer Author(s) Herrmann, L. (DE)
Yaremenko, I. A. (RU)
Çapci, A. (DE)
Struwe, J. (DE)
Tailor, D. (US)
Dheeraj, A. (US)
Hodek, Jan (UOCHB-X) RID, ORCID
Belyakova, Y. Y. (RU)
Radulov, P. S. (RU)
Weber, Jan (UOCHB-X) RID, ORCID
Malhotra, S. V. (US)
Terent'ev, A. O. (RU)
Ackermann, L. (DE)
Tsogoeva, S. B. (DE)Article number e202200005 Source Title ChemMedChem. - : Wiley - ISSN 1860-7179
Roč. 17, č. 9 (2022)Number of pages 6 s. Language eng - English Country DE - Germany Keywords artemisinin based hybrids ; anti-SARS-CoV-2 compounds ; anti-cancer compounds ; anti-leukemia agents OECD category Virology R&D Projects EF16_019/0000729 GA MŠMT - Ministry of Education, Youth and Sports (MEYS) Method of publishing Open access Institutional support UOCHB-X - RVO:61388963 UT WOS 000774531500001 EID SCOPUS 85127237188 DOI 10.1002/cmdc.202200005 Annotation The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause life-threatening diseases in millions of people worldwide, in particular, in patients with cancer, and there is an urgent need for antiviral agents against this infection. While in vitro activities of artemisinins against SARS-CoV-2 and cancer have recently been demonstrated, no study of artemisinin and/or synthetic peroxide-based hybrid compounds active against both cancer and SARS-CoV-2 has been reported yet. However, the hybrid drug's properties (e. g., activity and/or selectivity) can be improved compared to its parent compounds and effective new agents can be obtained by modification/hybridization of existing drugs or bioactive natural products. In this study, a series of new artesunic acid and synthetic peroxide based new hybrids were synthesized and analyzed in vitro for the first time for their inhibitory activity against SARS-CoV-2 and leukemia cell lines. Several artesunic acid-derived hybrids exerted a similar or stronger potency against K562 leukemia cells (81-83 % inhibition values) than the reference drug doxorubicin (78 % inhibition value) and they were also more efficient than their parent compounds artesunic acid (49.2 % inhibition value) and quinoline derivative (5.5 % inhibition value). Interestingly, the same artesunic acid-quinoline hybrids also show inhibitory activity against SARS-CoV-2 in vitro (EC50 13-19 mu m) and no cytotoxic effects on Vero E6 cells (CC50 up to 110 mu M). These results provide a valuable basis for design of further artemisinin-derived hybrids to treat both cancer and SARS-CoV-2 infections. Workplace Institute of Organic Chemistry and Biochemistry Contact asep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Jana Procházková, Tel.: 220 183 418 Year of Publishing 2023 Electronic address https://doi.org/10.1002/cmdc.202200005
Number of the records: 1